Hospital
ST. Joseph Health Northern California, LLC
ST. Joseph Health Northern California, LLC was paid $28.68M by Medicaid between Aug 2018 and Nov 2024, across 323 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoST. JOSEPH HEALTH NORTHERN CALIFORNIA, LLC
EUREKA, CA 95501
EUREKA, CA 95501
33aNPI1609858950assigned 11/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.68M
24GClaims705,992
24DCodes billed323
24AFirst – last monthAug 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#94 of 410
Median peer was paid$6.90M
This provider vs. median4.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 242 | $5K | |
| 2019 | 80,641 | $3.28M | |
| 2020 | 103,924 | $4.41M | |
| 2021 | 124,566 | $5.06M | |
| 2022 | 141,964 | $5.30M | |
| 2023 | 146,717 | $6.23M | |
| 2024incomplete | 107,938 | $4.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 49,657 | 40,088 | $4.70M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 13% | 46,415 | 39,630 | $3.69M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 3,568 | 3,486 | $1.11M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 21,104 | 4,370 | $788K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 4,195 | 4,013 | $773K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.5% | 7,846 | 6,522 | $728K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 6,693 | 4,649 | $704K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 8,418 | 7,286 | $694K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 2,853 | 2,836 | $612K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 14,253 | 12,957 | $534K |
| 99201 | 1.8% | 3,349 | 2,266 | $503K | |
| J3490 | Unclassified drugs | 1.7% | 66,047 | 30,777 | $478K |
311 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 8,313 | $473K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.6% | 1,395 | $470K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.6% | 3,325 | $458K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.6% | 1,181 | $447K |
| G9012 | Other specified case management service not elsewhere classified | 1.5% | 2,852 | $430K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 7,727 | $393K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 4,781 | $389K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 1,289 | $378K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 567 | $362K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.1% | 2,306 | $326K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 7,734 | $295K |
| 80053 | Comprehensive metabolic panel | <1% | 38,718 | $286K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,110 | $283K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 721 | $268K |
| 72141 | <1% | 732 | $252K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,979 | $227K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,787 | $223K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,373 | $217K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 710 | $203K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 543 | $199K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,814 | $187K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,603 | $181K |
| 97750 | <1% | 2,329 | $181K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,725 | $175K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,842 | $175K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,103 | $174K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,034 | $169K |
| 76830 | Ultrasound, transvaginal | <1% | 1,624 | $155K |
| 97139 | <1% | 3,987 | $154K | |
| 97010 | <1% | 3,982 | $153K | |
| 77066 | Tomosynthesis, mammo | <1% | 899 | $147K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,892 | $140K |
| 73221 | <1% | 381 | $139K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,508 | $131K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 306 | $114K |
| 71250 | <1% | 569 | $112K | |
| 76770 | <1% | 1,081 | $107K | |
| 76642 | <1% | 1,339 | $101K | |
| 70486 | <1% | 422 | $99K | |
| 93971 | <1% | 602 | $96K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,779 | $93K |
| 83880 | <1% | 3,903 | $91K | |
| 59025 | Fetal non-stress test | <1% | 2,749 | $90K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,539 | $87K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,371 | $87K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,636 | $85K |
| 73630 | <1% | 2,167 | $78K | |
| 73030 | <1% | 1,970 | $77K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,497 | $75K |
| 95811 | <1% | 205 | $71K | |
| 93017 | <1% | 620 | $69K | |
| 73610 | <1% | 1,740 | $68K | |
| 84484 | <1% | 8,972 | $63K | |
| 73130 | <1% | 1,594 | $62K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 263 | $62K |
| 96367 | <1% | 1,024 | $60K | |
| 72100 | <1% | 1,424 | $60K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 947 | $60K |
| 76536 | <1% | 763 | $56K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,150 | $55K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,892 | $54K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 626 | $54K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,531 | $52K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,318 | $50K |
| 90715 | <1% | 1,121 | $49K | |
| 73562 | <1% | 1,339 | $47K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,390 | $46K |
| 87631 | <1% | 929 | $46K | |
| 83605 | <1% | 5,653 | $44K | |
| 73110 | <1% | 1,113 | $43K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,467 | $42K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,468 | $42K |
| 83690 | <1% | 8,632 | $41K | |
| 72110 | <1% | 619 | $41K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,639 | $41K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 530 | $40K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,506 | $37K |
| 72040 | <1% | 958 | $35K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,876 | $33K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,512 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,240 | $32K |
| 71271 | <1% | 297 | $32K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,653 | $32K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,629 | $32K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,219 | $31K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 818 | $30K |
| 73502 | <1% | 706 | $30K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 452 | $29K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,301 | $28K |
| 87040 | <1% | 3,256 | $27K | |
| 73564 | <1% | 642 | $27K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 563 | $27K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,182 | $26K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,113 | $26K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 561 | $25K |
| 80061 | Lipid panel | <1% | 2,654 | $25K |
| 85055 | <1% | 1,117 | $25K | |
| 81001 | <1% | 8,823 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,271 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,071 | $24K |
| 97799 | <1% | 610 | $23K | |
| 74018 | <1% | 984 | $23K | |
| 80305 | <1% | 1,986 | $23K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 671 | $23K |
| 85610 | <1% | 7,507 | $22K | |
| 96415 | <1% | 392 | $21K | |
| 99285 | Emergency room visit (most serious) | <1% | 43 | $21K |
| 83735 | <1% | 4,202 | $21K | |
| 99152 | <1% | 326 | $20K | |
| 73080 | <1% | 488 | $19K | |
| 99070 | <1% | 1,078 | $19K | |
| 81003 | <1% | 9,928 | $18K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,880 | $18K |
| 97165 | <1% | 210 | $16K | |
| 85027 | <1% | 2,921 | $15K | |
| 87077 | <1% | 2,160 | $15K | |
| 85379 | <1% | 2,156 | $15K | |
| 86140 | <1% | 4,107 | $15K | |
| 84439 | <1% | 2,128 | $14K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 61 | $14K |
| 87186 | <1% | 2,046 | $14K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,227 | $14K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 673 | $13K |
| Z9725 | <1% | 301 | $13K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 823 | $13K |
| 77062 | <1% | 101 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 153 | $12K |
| 82728 | <1% | 1,210 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,774 | $11K |
| 93976 | <1% | 40 | $11K | |
| 88142 | <1% | 2,472 | $11K | |
| 96523 | <1% | 702 | $11K | |
| 73140 | <1% | 437 | $11K | |
| 82378 | <1% | 814 | $11K | |
| 81025 | <1% | 3,741 | $10K | |
| 0450 | Emergency room services | <1% | 227 | $9K |
| 76801 | <1% | 114 | $9K | |
| 82607 | <1% | 766 | $9K | |
| 96417 | <1% | 160 | $9K | |
| 94729 | <1% | 132 | $9K | |
| 93970 | <1% | 38 | $8K | |
| 87081 | <1% | 1,774 | $8K | |
| 72050 | <1% | 144 | $8K | |
| 82746 | <1% | 723 | $8K | |
| 83615 | <1% | 1,845 | $8K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 299 | $8K |
| 77065 | Tomosynthesis, mammo | <1% | 54 | $7K |
| 87400 | <1% | 788 | $7K | |
| 77336 | <1% | 58 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 463 | $7K |
| 76870 | <1% | 95 | $7K | |
| 87070 | <1% | 1,187 | $7K | |
| 85730 | <1% | 1,674 | $7K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 367 | $7K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $7K |
| 73620 | <1% | 255 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 417 | $7K |
| 82805 | <1% | 323 | $7K | |
| 82962 | <1% | 2,283 | $6K | |
| 83550 | <1% | 1,122 | $6K | |
| 85652 | <1% | 3,270 | $6K | |
| 83540 | <1% | 1,330 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 90 | $6K |
| 86850 | <1% | 2,787 | $6K | |
| 94727 | <1% | 131 | $6K | |
| 94010 | <1% | 126 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 147 | $6K |
| 86901 | <1% | 2,755 | $6K | |
| 86900 | <1% | 2,754 | $6K | |
| 62323 | <1% | 124 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 38 | $5K |
| 93880 | <1% | 25 | $5K | |
| 86803 | <1% | 447 | $5K | |
| 10060 | <1% | 128 | $5K | |
| 82077 | <1% | 308 | $5K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 633 | $4K |
| 73590 | <1% | 128 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 174 | $4K |
| 84702 | <1% | 451 | $4K | |
| 73090 | <1% | 122 | $4K | |
| 82570 | <1% | 1,074 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 493 | $4K |
| 88342 | <1% | 295 | $4K | |
| 70498 | <1% | 12 | $4K | |
| 87075 | <1% | 564 | $4K | |
| 80143 | <1% | 201 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 416 | $4K |
| 96368 | <1% | 123 | $3K | |
| 84100 | <1% | 972 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 301 | $3K |
| 72072 | <1% | 64 | $3K | |
| 71101 | <1% | 66 | $3K | |
| 73120 | <1% | 142 | $3K | |
| Z7502 | <1% | 80 | $3K | |
| 87205 | <1% | 1,101 | $3K | |
| 86141 | <1% | 343 | $3K | |
| 88304 | <1% | 486 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $3K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 245 | $3K |
| 95816 | <1% | 37 | $3K | |
| 93246 | <1% | 138 | $3K | |
| 95806 | <1% | 12 | $3K | |
| 80179 | <1% | 183 | $3K | |
| 87340 | <1% | 392 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 337 | $3K |
| 99153 | Mod sedat endo service >5yrs | <1% | 155 | $3K |
| 93225 | <1% | 41 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 210 | $3K |
| 77280 | <1% | 12 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 398 | $3K |
| 82784 | <1% | 271 | $2K | |
| 12001 | <1% | 87 | $2K | |
| 87420 | <1% | 1,041 | $2K | |
| 82550 | <1% | 548 | $2K | |
| 96402 | <1% | 140 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 72 | $2K |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 206 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $2K |
| 80074 | <1% | 69 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 42 | $2K |
| 94375 | <1% | 54 | $2K | |
| 84156 | <1% | 798 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 273 | $2K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 383 | $2K |
| 95819 | <1% | 26 | $2K | |
| 87147 | <1% | 531 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 108 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 98 | $2K |
| 76857 | <1% | 27 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 287 | $1K |
| 86300 | <1% | 97 | $1K | |
| 76882 | <1% | 103 | $1K | |
| 86592 | <1% | 546 | $1K | |
| 84145 | <1% | 77 | $1K | |
| 80164 | <1% | 139 | $1K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 190 | $1K |
| Z7610 | <1% | 102 | $1K | |
| 73560 | <1% | 40 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 99 | $1K |
| 88341 | <1% | 12 | $1K | |
| 86038 | <1% | 158 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 139 | $1K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 12 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 32 | $975.66 |
| 84550 | <1% | 292 | $961.30 | |
| 80069 | <1% | 118 | $930.69 | |
| 84466 | <1% | 109 | $913.84 | |
| 74022 | <1% | 14 | $893.81 | |
| 82803 | <1% | 89 | $876.90 | |
| 87210 | <1% | 300 | $834.79 | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 13 | $832.56 |
| 86003 | <1% | 15 | $813.28 | |
| 86706 | <1% | 110 | $809.37 | |
| 85018 | <1% | 454 | $770.15 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 106 | $735.72 |
| 73522 | <1% | 16 | $730.65 | |
| 84153 | <1% | 51 | $689.08 | |
| 87088 | <1% | 95 | $653.17 | |
| 85007 | <1% | 292 | $642.92 | |
| 86762 | <1% | 58 | $556.35 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 26 | $516.02 |
| 12011 | <1% | 12 | $511.20 | |
| 93242 | <1% | 27 | $463.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 35 | $458.64 |
| 86780 | <1% | 47 | $428.64 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 187 | $423.72 |
| 83970 | <1% | 14 | $409.73 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 13 | $381.16 |
| 76937 | <1% | 12 | $364.02 | |
| 12002 | <1% | 12 | $340.80 | |
| 73100 | <1% | 13 | $297.33 | |
| 84703 | <1% | 64 | $273.18 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 53 | $264.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 16 | $258.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 56 | $245.30 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 29 | $230.27 |
| 88307 | <1% | 14 | $227.89 | |
| 80178 | <1% | 43 | $213.98 | |
| 80306 | <1% | 14 | $209.76 | |
| 0250 | <1% | 242 | $206.59 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 36 | $197.43 |
| 83921 | <1% | 16 | $187.88 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $182.15 |
| 29125 | <1% | 15 | $177.45 | |
| 82105 | <1% | 25 | $175.00 | |
| 84403 | <1% | 14 | $173.41 | |
| 86160 | <1% | 19 | $168.47 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $161.50 |
| 84481 | <1% | 14 | $150.55 | |
| 82951 | <1% | 16 | $144.32 | |
| 82565 | <1% | 39 | $143.07 | |
| 80076 | <1% | 27 | $138.98 | |
| 83001 | <1% | 12 | $131.30 | |
| 82140 | <1% | 13 | $118.71 | |
| 86431 | <1% | 27 | $114.07 | |
| 84425 | <1% | 12 | $106.56 | |
| 86200 | <1% | 12 | $89.37 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 329 | $88.97 |
| 80047 | <1% | 12 | $85.02 | |
| 87427 | <1% | 12 | $84.72 | |
| 87045 | <1% | 12 | $79.92 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 747 | $72.40 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 12 | $61.54 |
| 86225 | <1% | 12 | $60.92 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 644 | $51.04 |
| 85046 | <1% | 14 | $49.74 | |
| 87899 | <1% | 12 | $46.80 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 687 | $17.90 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 72 | $5.41 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $0.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Parent organizationST. JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.